Log in

NASDAQ:LQDALiquidia Technologies Stock Price, Forecast & News

-0.24 (-2.53 %)
(As of 05/29/2020 04:00 PM ET)
Today's Range
Now: $9.24
50-Day Range
MA: $6.77
52-Week Range
Now: $9.24
Volume356,664 shs
Average Volume201,190 shs
Market Capitalization$262.14 million
P/E RatioN/A
Dividend YieldN/A
Liquidia Technologies, Inc., a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of human therapeutics. Its lead product candidate, LIQ861, an inhaled dry powder formulation of treprostinil that is in Phase III clinical trials used for the treatment of pulmonary arterial hypertension. The company is also developing LIQ865, which completed Phase 1 clinical trials for the treatment of local post-operative pain. It has collaboration agreements with GlaxoSmithKline plc and the University of North Carolina. Liquidia Technologies, Inc. was founded in 2004 and is headquartered in Morrisville, North Carolina.
Read More
Liquidia Technologies logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.13 out of 5 stars

Industry, Sector and Symbol

Industry Surgical & medical instruments
Current SymbolNASDAQ:LQDA



Sales & Book Value

Annual Sales$8.07 million
Book Value$0.77 per share


Net Income$-47,580,000.00


Market Cap$262.14 million
Next Earnings Date8/13/2020 (Estimated)
OptionableNot Optionable

Receive LQDA News and Ratings via Email

Sign-up to receive the latest news and ratings for LQDA and its competitors with MarketBeat's FREE daily newsletter.

Liquidia Technologies (NASDAQ:LQDA) Frequently Asked Questions

How has Liquidia Technologies' stock been impacted by COVID-19 (Coronavirus)?

Liquidia Technologies' stock was trading at $3.66 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, LQDA stock has increased by 152.5% and is now trading at $9.24. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Liquidia Technologies?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Liquidia Technologies in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Liquidia Technologies.

When is Liquidia Technologies' next earnings date?

Liquidia Technologies is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Liquidia Technologies.

How were Liquidia Technologies' earnings last quarter?

Liquidia Technologies Inc (NASDAQ:LQDA) issued its earnings results on Monday, May, 11th. The company reported ($0.52) EPS for the quarter, topping analysts' consensus estimates of ($0.53) by $0.01. View Liquidia Technologies' earnings history.

What price target have analysts set for LQDA?

3 analysts have issued 12-month target prices for Liquidia Technologies' shares. Their forecasts range from $30.00 to $41.00. On average, they expect Liquidia Technologies' share price to reach $37.00 in the next twelve months. This suggests a possible upside of 300.4% from the stock's current price. View analysts' price targets for Liquidia Technologies.

What are Wall Street analysts saying about Liquidia Technologies stock?

Here are some recent quotes from research analysts about Liquidia Technologies stock:
  • 1. According to Zacks Investment Research, "Liquidia Technologies, Inc. is a late-stage clinical biopharmaceutical company. It focused on the development and commercialization of human therapeutics using our proprietary PRINT technology to transform the lives of patients. The company's product candidate consists of LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain which are in clinical stage. Liquidia Technologies, Inc. is based in NC, United States. " (5/19/2020)
  • 2. Wedbush analysts commented, "We base our $27 price target on a sum-of-the-parts analysis derived from: (1) the P/E value of La Jolla’s current commercial business (Giapreza); (2) an NPV of its pipeline (LJPC-401); and (3) our estimated year-end 2019 fully diluted net cash of $2.03/share to arrive at our price target. We value the current commercial business at $12.94 per share and the pipeline at $11.99 per share. The commercial business value is based on a P/E multiple assumption of 30x our 2024E EPS of $0.75, discounted at 15%." (6/28/2019)

Has Liquidia Technologies been receiving favorable news coverage?

Media stories about LQDA stock have trended negative recently, according to InfoTrie Sentiment. The research group identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Liquidia Technologies earned a media sentiment score of -2.6 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutLiquidia Technologies.

Are investors shorting Liquidia Technologies?

Liquidia Technologies saw a increase in short interest in April. As of April 30th, there was short interest totaling 566,400 shares, an increase of 44.4% from the April 15th total of 392,200 shares. Based on an average trading volume of 132,100 shares, the short-interest ratio is presently 4.3 days. Currently, 3.8% of the company's shares are short sold. View Liquidia Technologies' Current Options Chain.

Who are some of Liquidia Technologies' key competitors?

What other stocks do shareholders of Liquidia Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Liquidia Technologies investors own include Crispr Therapeutics (CRSP), Agile Therapeutics (AGRX), vTv Therapeutics (VTVT), Amarin (AMRN), Protalix Biotherapeutics (PLX), VBI Vaccines (VBIV), Vaxart (VXRT), Zynerba Pharmaceuticals (ZYNE), Anavex Life Sciences (AVXL) and Aytu Bioscience (AYTU).

Who are Liquidia Technologies' key executives?

Liquidia Technologies' management team includes the following people:
  • Mr. Neal F. Fowler, CEO & Director (Age 57)
  • Mr. Robert A. Lippe, Chief Operations Officer (Age 54)
  • Mr. William R. Kenan Jr., Co-Founder
  • Dr. Ginger Denison, Co-Founder
  • Mr. Timothy M. Albury, Interim Chief Financial Officer (Age 50)

When did Liquidia Technologies IPO?

(LQDA) raised $50 million in an initial public offering on Thursday, July 26th 2018. The company issued 4,500,000 shares at $10.00-$12.00 per share. Jefferies and Cowen served as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers.

What is Liquidia Technologies' stock symbol?

Liquidia Technologies trades on the NASDAQ under the ticker symbol "LQDA."

Who are Liquidia Technologies' major shareholders?

Liquidia Technologies' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (2.85%), State Street Corp (0.77%), Geode Capital Management LLC (0.60%), Parametric Portfolio Associates LLC (0.19%), Bank of New York Mellon Corp (0.15%) and Alambic Investment Management L.P. (0.06%). Company insiders that own Liquidia Technologies stock include Arthur S Kirsch, Benjamin Maynor, Eshelman Ventures, Llc, Kevin K Gordon, Plc Glaxosmithkline, Timothy Albury and Viii Lp Canaan. View institutional ownership trends for Liquidia Technologies.

Which institutional investors are selling Liquidia Technologies stock?

LQDA stock was sold by a variety of institutional investors in the last quarter, including Squarepoint Ops LLC, BlackRock Inc., Morgan Stanley, Parametric Portfolio Associates LLC, UBS Group AG, JPMorgan Chase & Co., and Alambic Investment Management L.P.. View insider buying and selling activity for Liquidia Technologies.

Which institutional investors are buying Liquidia Technologies stock?

LQDA stock was bought by a variety of institutional investors in the last quarter, including State Street Corp, Sigma Planning Corp, Bank of New York Mellon Corp, Wells Fargo & Company MN, and Geode Capital Management LLC. Company insiders that have bought Liquidia Technologies stock in the last two years include Arthur S Kirsch, Eshelman Ventures, Llc, Plc Glaxosmithkline, and Viii Lp Canaan. View insider buying and selling activity for Liquidia Technologies.

How do I buy shares of Liquidia Technologies?

Shares of LQDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Liquidia Technologies' stock price today?

One share of LQDA stock can currently be purchased for approximately $9.24.

How big of a company is Liquidia Technologies?

Liquidia Technologies has a market capitalization of $262.14 million and generates $8.07 million in revenue each year. The company earns $-47,580,000.00 in net income (profit) each year or ($2.59) on an earnings per share basis.

What is Liquidia Technologies' official website?

The official website for Liquidia Technologies is www.liquidia.com.

How can I contact Liquidia Technologies?

Liquidia Technologies' mailing address is 419 DAVIS DRIVE SUITE 100, MORRISVILLE NC, 27560. The company can be reached via phone at 919-328-4400 or via email at [email protected]

This page was last updated on 6/1/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.